Finch Therapeutics Group Inc

NASDAQ:FNCH   4:00:00 PM EDT
0.93
-0.02 (-2.13%)
Earnings Announcements

Finch Therapeutics Reports Q3 2022 Financial Results

Published: 11/10/2022 12:53 GMT
Finch Therapeutics Group Inc (FNCH) - Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results.
Finch Therapeutics Group Inc - Patient Dosing Underway in Prism4 Phase 3 Trial of Cp101 in Recurrent Cdi.
Finch Therapeutics Group Inc - Topline Prism4 Data Anticipated in H1 2024.
Finch Therapeutics Group Inc - Anticipated Cash Runway Into Q2 2024.
Finch Therapeutics Group Inc - Cash and Cash Equivalents As of September 30, 2022 Were $85.3 Million, Compared to $133.5 Million As of December 31, 2021.
Finch Therapeutics Group Inc - Qtrly Loss per Share $0.85.
Revenue is expected to be $0.2 Million
Adjusted EPS is expected to be -$0.41

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.